Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
91.3
NK cell percentage (%)Wording
Definitive
How definitive the wording is.Announced details
Phicello NK/T advancePhicello NK/T SupplementPhicello NK/T advance DIRECT
Applicable field (uses covered by this announcement)
Regenerative medicine and gene therapy, research use
Launch date19 May 2026 (already launched)
What the company reported numerically
Quantitative Effects
NK cell percentage of 91.3% achieved, reduced contamination risk, improved work efficiency
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Phicello NK/T advance, Phicello NK/T Supplement, Phicello NK/T advance DIRECT |
| Launch date | 19 May 2026 (already launched) |
| Applicable area | Regenerative medicine and gene therapy, research use |
| Quantitative Effects | NK cell percentage of 91.3% achieved, reduced contamination risk, improved work efficiency |
Items this document does not state (14)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To contribute to the regenerative medicine and gene therapy markets, and to people's lives, through the development, expansion of the product lineup and sale of products linked to efficacy verification and supporting evidence.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.